Form 4: Zimmer Biomet Director Louis Shapiro Reports Acquisition of Equity Compensation Units

Zimmer Biomet Holdings, Inc. Director Louis Shapiro reported the acquisition of 810.46 phantom stock units and 1,404.798 restricted stock units on May 29, 2025, as part of his compensation.

Summary

• Louis Shapiro, a Director at Zimmer Biomet Holdings, Inc. (ZBH), reported transactions on May 29, 2025, involving the acquisition of equity-based compensation.
• He acquired 810.46 phantom stock units, which are convertible at a price of $92.54 per unit. These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Following this transaction, Shapiro beneficially owns 2,046.114 phantom stock units, which includes 2.894 units accrued on April 30, 2025, from a dividend reinvestment provision.
• Shapiro also acquired 1,404.798 Restricted Stock Units (RSUs). These RSUs are immediately 100% vested.
• After the RSU acquisition, Shapiro beneficially owns 2,473.789 Restricted Stock Units.
• The RSUs are subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a director, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. No negative operational or financial news is present.

Positives

• The acquisition of phantom stock units and restricted stock units by a director indicates continued alignment of interests with shareholders through equity-based compensation.
• The immediate 100% vesting of the Restricted Stock Units suggests a strong retention mechanism for the director.

Future Outlook

This Form 4 filing primarily details insider transactions related to director compensation and does not provide forward-looking statements or guidance on the company's future financial performance or strategic outlook.

Industry Context

This filing is a routine insider transaction report related to director compensation within the medical technology industry. It does not offer insights into broader industry trends, competitive dynamics, or market conditions.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially encouraging long-term value creation and good governance.

Next Steps

• Phantom stock units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
• Restricted Stock Units will be subject to mandatory deferral until the later of the reporting person's termination of service as a Director or three years after the grant date.

Key Dates

Recommendation

Keywords

Zimmer Biomet Holdings, ZBH, Louis Shapiro, SEC Form 4, Insider Transaction, Phantom Stock Units, Restricted Stock Units, Director Compensation, Equity Compensation, Deferred Compensation Plan